Company Overview and News

Fitch assigns Melstacorp first-time ‘AAA(lka)’ rating; outlook stable

2018-10-03 lankabusinessonline
Oct 03, 2018 (LBO) – Fitch Ratings has assigned Sri Lanka-based conglomerate Melstacorp a National Long-Term Rating of ‘AAA(lka)’ with a stable outlook.

Asia Frontier Capital - Sri Lanka Travel Report

2018-09-13 seekingalpha
Infrastructure projects such as the Colombo International Financial City can help improve long term economic prospects for Sri Lanka.

eChannelling launches its digital services at District Hospitals in Sri Lanka

2018-08-21 lankabusinessonline
Aug 21, 2018 (LBO) – A Fully-owned subsidiary of Sri Lanka Telecom, e-Channelling PLC recently launched its service at Ampara General Hospital marking it as the first district Hospital in Sri Lanka to have the service.

Sri Lanka Telecom (SLTL) to issue 90mn shares private placement, price TBD

2018-08-13 lankabusinessonline
August 13, 2018 (LBO) – Trading in shares of Colombo Stock Exchange (CSE) listed Sri Lanka Telecom (SLTL) were halted today pending an announcement of un upcoming private placement.

Fitch removes Rating Watch Negative on Distilleries; affirms at AAA(lka)

2018-07-13 lankabusinessonline
July 13, 2018 (LBO) – Fitch Ratings has removed the Rating Watch Negative on Distilleries Company’s National Long-Term Rating, and has affirmed the rating at ‘AAA(lka)’.

Austin To Be Replaced By Another Fernando As President’s Secretary

2018-06-07 colombotelegraph
Austin Fernando‘s short stint as the Secretary to the President Maithripala Sirisena is set to end soon with high-ranking Sirisena aides actively looking for a replacement, Colombo Telegraph learns.

Austin To Be Replaced Most Probably By Another Fernando As President’s Secretary

2018-06-07 colombotelegraph
Austin Fernando‘s short stint as the Secretary to the President Maithripala Sirisena is set to end soon with high-ranking Sirisena aides actively looking for a replacement, Colombo Telegraph learns.

What About Nepotism & Cronyism?

2018-05-06 colombotelegraph
In the wake of President’s Chief of Staff and Chairman State Timber Corporation being nabbed by Commission to Investigate Allegations of Bribery or Corruption (CIABOC)in a five-star hotel car park accepting a bribe of Rs 20 million as part of a bribe from an Indian businessman, local media had published a statement by Secretary to President.

Sri Lanka’s telco merger to relieve competitive pressure: Fitch

2018-05-01 lankabusinessonline
May 01, 2018 (LBO) – The merger between Hutchison Telecommunications Lanka (Private) Ltd and Etisalat Lanka (Private) Ltd is likely to relieve some competitive pressures that have undermined Sri Lankan telecom companies’ revenue and EBITDA growth in recent years, Fitch Ratings said..

Fitch affirms Sri Lanka’s Dialog Axiata at AAA(lka); outlook stable

2018-04-05 lankabusinessonline
Fitch Ratings-Singapore/Colombo- 4 April 2018: Fitch Ratings has affirmed Sri Lanka-based telecom company Dialog Axiata PLC’s National Long-Term Rating at ‘AAA(lka)’. The Outlook is Stable.

Daily income of state telcos surged after social media blocked: President

2018-03-14 lankabusinessonline
Mar 14, 2018 (LBO) – Sri Lanka’s President Maithripala Sirisena says daily income of state-owned telecommunication sector players have jumped significantly after restricting access to several social media sites.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...